The meeting brings together individuals who are working on drug/xenobiotic research across a diverse range of fields such as clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal…
Read updateFounded on the technology of Prof Lyle Armstrong and Prof Majlinda Lako from Newcastle University, the company is at the forefront of the production and differentiation of human induced…
Read updateTo watch the full video click here.
Read updateAbstract Despite considerable effort and significant therapeutic advances, age-related macular degeneration (AMD) remains the commonest cause of blindness in the developed world. Progressive late-stage AMD with outer retinal degeneration currently…
Read updateDr Brown is the developer of the aProximateTM assay for measuring kidney transporter and nephrotoxicity licensed exclusively to Newcells Biotech. The World Preclinical Congress is a key networking event focusing on…
Read updateDr Chichagova will be talking about Retinitis Pigmentosa, one of the most common forms of inherited blindness affecting over 1 million people worldwide.With no effective treatment available for Retinitis…
Read updateUsing statistical modelling, Dr Chichagova was able to improve the differentiation outcome of human induced pluripotent stem cells to retinal organoids, which were subsequently successfully tested with a toxicologically relevant test compound. As…
Read updateHilton Gateshead – 16th-18th April https://www.thebts.org/bts-annual-congress-2018/ The Newcells Biotech team will be attending the British Toxicological Society Annual Congress 2018 that is taking place in Gateshead on 16th-18th April. Newcells Biotech staff…
Read updateNewcells Biotech in partnership with Newcastle University has been awarded further funding from the NC3R CRACK IT project to create 3D retinal organoids that more closely recapitulate the structure…
Read update